3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
2
Gastro-enteropancreatic neuroendocrine tumor
2
Pancreatitis
1
Pancreatic Intraductal Neoplasms
1
Meningioma
1
Fistula
1
Duodenal Neoplasms
1
Carcinoid Tumor
1
Adenoma, Islet Cell
1
Interventions
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Everolimus
3
lutetium Lu 177 dotatate
2
Temozolomide
2
Sunitinib
2
sargramostim
1
montanide ISA 51
1
lanreotide
1
incomplete Freund's adjuvant
1
fludarabine phosphate
1
belzutifan
1
Sorafenib
1
Radiofrequency Ablation
1
Octreotide
1
Interleukin-13
1
Histocompatibility Testing
1
Gefitinib
1
Fulvestrant
1
Fluorodeoxyglucose F18
1
Cytoreduction Surgical Procedures
1
Cyclophosphamide
1
Colony-Stimulating Factors
1
Capecitabine
1
Blood Specimen Collection
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Adenoma, Islet Cell
×
Octreotide
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled